Delphi Diagnostics

Delphi Diagnostics guides personalized breast cancer therapy decisions with SET.

Uncategorized

Delphi DiagnosticsTM Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX Breast Recurrence Score®) in Node-Positive Breast Cancer

by

Published in the Journal of Clinical Oncology, SET2,3, and Recurrence Score were independent of each other and provided additive prognostic information when combined in post-menopausal patients with node-positive breast cancer. Houston, TX, March 09, 2023 – Delphi Diagnostics, Inc announces the publication entitled, “Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence […]

Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™

by

Houston, TX, October 27th, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer. The SET2,3TM test helps to determine which patients with HR+ tumors will benefit from endocrine therapy. Those patients whose […]

Delphi DiagnosticsTM Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037

by

Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio. Houston, TX, September 22, 2022 – Delphi DiagnosticsTM Inc. today announced that the United States Patent and Trademark Office has issued US11,459,617 on […]

SET2,3TM Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022

by

For patients diagnosed with ER+ breast cancer and low endocrine sensitivity (a Low SET2,3 index), dose-dense chemotherapy was associated with superior disease-free survival (DFS) and overall survival (OS) outcomes when compared to non-dose-dense regimens. Houston, TX, June 13 2022 – Delphi Diagnostics Inc. announced today the inclusion of Delphi’s proprietary Sensitivity to Endocrine Therapy test, […]